Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 26;27(2):573–586. doi: 10.1038/s41418-019-0373-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Mice Lacking Prmt7 Exhibit Delayed Muscle Regeneration. a The scheme of cardiotoxin injury and representative images of hematoxylin and eosin stained sections of TA muscles from Prmt7^+/+ and Prmt7^−/− mice harvested at 0, 4, 7, 14 and 30 days post cardiotoxin injury (PID). Scale bar, 20μm. b Quantification of the number of eosin-positive myofibers from Prmt7^+/+ and Prmt7^−/− TA muscles at 7 days after injury. c, d Quantification of the cross-sectional area of Prmt7^+/+ and Prmt7^−/− TA muscles at 7 and 14 days following injury. Values are mean ± SEM (n = 3 mice per group). *P < 0.05, **P < 0.01. e Immunostaining of TA muscles from Prmt7^+/+ and Prmt7^−/− mice with anti- eMHC and anti-laminin antibodies at 4 and 7 days post injury. f Quantification of the number of eMHC-positive myofibers. Values are means ± SD. **P < 0.01, ***P < 0.001 (n = 3). g Quantitative RT-PCR analysis for various myogenic markers in Prmt7^+/+ and Prmt7^−/− TA muscles at indicated time points (post injury days 0, 4, 7 and 14) after CTX injury. Markers analyzed are Pax7, MyoD, Myogenin and eMHC. Values are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (n = 3). h Immunostaining of TA muscles from Prmt7^+/+ and Prmt7^−/− mice at 7 days after CTX injury with anti-Pax7 and anti-MyoD antibodies. i Quantification of the number of cells undergoing self-renewal (Pax7⁺/MyoD^-), activation (Pax7⁺/MyoD⁺) and differentiation (Pax7^-/MyoD⁺). Values are means ± SD. *P < 0.05, **P < 0.01 (n = 3)